SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: phoenix_rising who wrote (1447)8/18/2015 8:26:48 PM
From: eico20  Read Replies (1) of 2026
 
Rayva will be more of a factor for APRI than Femprox, at least in the next few years, and only if Femprox gets a partner deal and moving in the EU, it may never happen at this point, as pascoe said , if a big pharma partners Flib., then they could pitch femprox to that same big pharma co. as a second drug for them to pursue in that space of one drug so far, alot of if's there.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News